{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etrumadenant", "query": { "intervention": "Etrumadenant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etrumadenant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T19:43:34.446Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05915442", "title": "Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligometastatic Prostate Cancer" ], "interventions": [ { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Catherine Spina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 23, "start_date": "2023-07-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05915442" }, { "nct_id": "NCT03821246", "title": "Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Prostate Cancer", "Localized Prostate Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Oh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 68, "start_date": "2019-10-30", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 2, "location_summary": "San Francisco, California • St Louis, Missouri", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821246" }, { "nct_id": "NCT03720678", "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GastroEsophageal Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "etrumadenant", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-11-18", "completion_date": "2021-06-25", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 17, "location_summary": "Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03720678" }, { "nct_id": "NCT04262856", "title": "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Nonsquamous Non Small Cell Lung Cancer", "Squamous Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2020-05-28", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Whittier", "state": "California" }, { "city": "Englewood", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262856" }, { "nct_id": "NCT05177770", "title": "Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "SRF617", "type": "DRUG" }, { "name": "etrumadenant", "type": "DRUG" }, { "name": "zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2022-01-17", "completion_date": "2023-04-05", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 7, "location_summary": "Miami, Florida • Ann Arbor, Michigan • Las Vegas, Nevada + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05177770" }, { "nct_id": "NCT05633667", "title": "Study of Novel Treatment Combinations in Patients With Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Advanced or Metastatic Non-Small-Cell Lung Cancer", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Zimberelimab (ZIM)", "type": "DRUG" }, { "name": "Domvanalimab (DOM)", "type": "DRUG" }, { "name": "Sacituzumab govitecan-hziy (SG)", "type": "DRUG" }, { "name": "Etrumadenant (ETRUMA)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-03-16", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 11, "location_summary": "Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633667" }, { "nct_id": "NCT04660812", "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "m-FOLFOX-6 regimen", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2021-05-10", "completion_date": "2025-09-05", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660812" }, { "nct_id": "NCT05277012", "title": "A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2022-02-10", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277012" }, { "nct_id": "NCT05335941", "title": "A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-06-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335941" }, { "nct_id": "NCT05154136", "title": "A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2021-10-20", "completion_date": "2021-12-10", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-03T19:43:34.446Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05154136" } ] }